Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1995-06-06
1999-11-02
Peselev, Elli
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
536 551, 536 552, A61K 3170
Patent
active
059770880
ABSTRACT:
Pharmaceutical compositions from which effective non-toxic (to the patient) dosage amounts may be taken and applied to the skin and/or exposed tissue of a human, each effective dosage amount comprising pharmaceutical excipients suitable for topical application, an effective non-toxic dosage amount of a drug to treat and to assist to resolve a disease and/or condition of the skin and/or exposed tissue of a human and an effective non-toxic dosage amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or sub-units of hyaluronic acid sufficient to transport (to facilitate or cause the transport of) the drug, to a site in the skin including epidermis or exposed tissue of a disease or condition for percutaneous transport into the skin and/or exposed tissue to accumulate and remain there for a prolonged period of time and which is systemic independent acting.
REFERENCES:
patent: 2583096 (1952-01-01), Hadidian et al.
patent: 3042667 (1962-07-01), Flodin et al.
patent: 3247063 (1966-04-01), Pulver
patent: 3357784 (1967-12-01), Kasper et al.
patent: 3396081 (1968-08-01), Billek et al.
patent: 3436454 (1969-04-01), Nouvel
patent: 3792164 (1974-02-01), Bechtold et al.
patent: 3845201 (1974-10-01), Haddad et al.
patent: 3870791 (1975-03-01), Haddad et al.
patent: 3887703 (1975-06-01), Manoussos et al.
patent: 4003991 (1977-01-01), Krohn et al.
patent: 4045558 (1977-08-01), Smith et al.
patent: 4061722 (1977-12-01), Bodor et al.
patent: 4141973 (1979-02-01), Balazs
patent: 4240163 (1980-12-01), Galin
patent: 4255415 (1981-03-01), Chrai et al.
patent: 4271143 (1981-06-01), Schoenwald et al.
patent: 4272522 (1981-06-01), Balazs
patent: 4280954 (1981-07-01), Yannas et al.
patent: 4303676 (1981-12-01), Balazs
patent: 4328803 (1982-05-01), Pape
patent: 4470975 (1984-09-01), Berger et al.
patent: 4478822 (1984-10-01), Haslam et al.
patent: 4487865 (1984-12-01), Balazs et al.
patent: 4500676 (1985-02-01), Balazs
patent: 4517295 (1985-05-01), Bracke
patent: 4582865 (1986-04-01), Balazs et al.
patent: 4629623 (1986-12-01), Balazs et al.
patent: 4636524 (1987-01-01), Balazs et al.
patent: 4684627 (1987-08-01), LeVeen et al.
patent: 4686288 (1987-08-01), Lormeau et al.
patent: 4711780 (1987-12-01), Fahim
patent: 4713448 (1987-12-01), Balazs et al.
patent: 4716224 (1987-12-01), Sakurai et al.
patent: 4725585 (1988-02-01), Wenge et al.
patent: 4736024 (1988-04-01), Della Valle et al.
patent: 4746504 (1988-05-01), Nimrod et al.
patent: 4755544 (1988-07-01), Makino et al.
patent: 4782046 (1988-11-01), Brown et al.
patent: 4784990 (1988-11-01), Nimrod et al.
patent: 4784991 (1988-11-01), Nimrod et al.
patent: 4795741 (1989-01-01), Leshchiner et al.
patent: 4801619 (1989-01-01), Lindblad
patent: 4804537 (1989-02-01), Bergman et al.
patent: 4808576 (1989-02-01), Schultz et al.
patent: 4814175 (1989-03-01), Tack et al.
patent: 4820732 (1989-04-01), Shell et al.
patent: 4840941 (1989-06-01), Ueno et al.
patent: 4851521 (1989-07-01), della Valle et al.
patent: 4853224 (1989-08-01), Wong
patent: 4853226 (1989-08-01), Machida et al.
patent: 4855134 (1989-08-01), Yamahira et al.
patent: 4863907 (1989-09-01), Sakurai et al.
patent: 4877619 (1989-10-01), Richer
patent: 4879282 (1989-11-01), Saliba, Jr.
patent: 4900550 (1990-02-01), Lowry
patent: 4912093 (1990-03-01), Michaeli
patent: 4913898 (1990-04-01), Altobelli et al.
patent: 4937254 (1990-06-01), Sheffield et al.
patent: 4937270 (1990-06-01), Hamilton et al.
patent: 4944941 (1990-07-01), Ammann
patent: 4957744 (1990-09-01), della Valle
patent: 4963666 (1990-10-01), Malson
patent: 4965353 (1990-10-01), della Valle
patent: 5092841 (1992-03-01), Spears
patent: 5095037 (1992-03-01), Iwamitsu
patent: 5116331 (1992-05-01), della Valle
patent: 5116864 (1992-05-01), March et al.
patent: 5442053 (1995-08-01), Della Valle et al.
Abatangelo G, Martelli M, Vecchia P. Healing of hyaluronic acid-enriched wounds: Histological observations. J. Surgical Research 1983; 35: 410-416.
Abatangelo G, Corvito R, et al. Cell detachment mediated by hyaluronic acid. Exp. Cell Res. 1982; 137: 73-78.
Adams JB. Steroid hormones and breast cancer. Dissertation Abstracts International 1981; 42(4): 1425B.
Ahlgren T, Jarstrand C. Hyaluronic acid enhances phagocytosis of human monocytes in vitro. J Clinical Immunology 1984; 4(3): 246-249.
Alaverdyan MI, Ter-Avetisyan AT. Effect of hyaluronidase, hyaluronic acid, and some other substances on postradiational experimental bacteriemai. Bulletin of Experimental Biology and Medicine 1967; 64(9): 967-969.
Alexander P. Ageing skin: Remedial measures. Manuf. Chemist 1985; Oct.: 35, 37, 39.
Altman RD, Kapila P, Dean DD, Howell DS. Future therapeutic trends in osteoarthritis. Scand. J. Rheumatology 1989; Suppl. 77: 37-42.
Ambroggio G, Barberis ML Trattamento di lesioni cutanee ad andamento cronico con acido ialuronico. Minerva Chirurgica 1969; 23(15): 815-818.
Anastassiades T, Robertson W. Modulation of mitogen-dependent lymphocyte stimulation by hyaluroniccid. J Rheum. 1984; 11(6): 729-734.
Appel A, Horwitz AL, Dorfman A. Cell-free synthesis of hyaluronic acid in marfan syndrome. J Biological Chemistry 1979; 254(23): 12199-12203.
Arzeno G, Miller D. Effect of sodium hyaluronate on corneal wound healing. Arch Ophthalmol 1982; 100: 152.
Aste L, Burattoni G. Osservazioni sull'impiego dell'acido jaluronico nel trattamento delle ulcere da decubito nelle sindromi midollari. Ospedali D'Italia Chirurgia 1967: 17(3): 315-322.
Balazs EA, Band P. Hyaluronic acid: Its structure and use. Cosmetics & Toiletries . Polymers in Cosmetics 1984; 99: 65-72.
Balazs EA, Freeman MI, et al. Hyaluronic acid and replacement of vitreous and aqueous humor. Modern Problems in Ophthalmology : Secondary Detachment of the Retina 1971; 10: 3-21.
Balazs EA, Gibbs DA. The rheological properties and biological function of hyaluronic acid. In: Chemistry and Molecular Biology of the Intercellullar Matrix. vol. III. New York: Academic Press, 1970. pp. 1241-1253.
Barondes SH. Bifunctional properties of Iectins: Lectins redefined. TIBS 1988; 13 (Dec.): 480-482.
Barron BA, et al. Comparison of the effects of viscoat and healon on postoperative intraocular pressure. Am. J. Ophthallmology 1985; 100: 377-384.
Bayer EA, Wilcher M. The use of the avidin-biotin complex as a tool in molecular biology. Methods of Biochemical Analysis. vol. 26: 1-45.
Ber A, Mikolajczyk H. Badania nad ukladem hialuronidaza--kwas hialuronowy. Wplyw kwasu hialuronowego na gojenie sie doswiad-czalnych wrzodow zoladka u szczurow. Patologia Polska 1957; 8: 31-36.
Biggar WD, Sturgess JM. Role of lysozyme in the microbicidal activity of rat alveolar macrophages. Infection and Immunity 1977; 16(3): 974-982.
Billek G, Billek D. Hyaluronsaure--Die Gesch . . . eines kosmetischen wirkstoffs. [Summary in English] Parfuemerie und Kosmetik 1988; 69(12): 768-790 & 792-795.
Binkhorst CD. Advantages and disadvantages of intracamerular Na-Hyaluronate (Healon) in intraocular lens surgery. Documenta Ophthalmologica 1981; 50: 233-235.
Blumenkrantz N, Asboe-Hansen G. Reaction of cationic groups of chlorpromazine with anionic macromolecules: Complexes with DNA, RNA, hyaluronic acid and heparin. Acta Pharmacol. et Toxiicol. 1974; 34: 27-32.
Boutet D, Voskamp K. L'acide hyaluronique: Proprietes et applications. Parfums, Cosmetiques, Aromes 1986; 68: 53-56.
Bowen BR, Nguyen T, Lasky LA. Characterization of a human homologue of the murine peripheral lymph node homing receptor. J Cell Biology 1989; 109(Jul.): 421-427.
Boyce ST, Christianson DJ, Hansbrough JF. Structure of a collagen-GAG dermal skin substitute optimized for cultured human epidermal keratinocytes. J. Biomedical Material Research 1988; 22: 939-957.
Brandstetter W, Kiesewetter E, Wohlzogen FX. Influencing experimental pathological changes i rodents with hyaluronic acid. [Translation of : Beeinflussung experimentell-pathologischer veranderungen bei nagern durch hyaluronsaure.] Archive for Experimental Pathology and Pharmacology / Archiv Fur Experimentelle Pathologie 1957; 231(2): 186-198.
Brandt K. Modification of chemot
Asculai Samuel Simon
Falk Rudolf Edger
Harper David William
Hochman David
Klein Ehud Shmuel
Hughes Ivor M.
Hughes Neil H.
Hyal Pharmaceutical Corporation
Peselev Elli
Sarkis Marcelo K.
LandOfFree
Formulations containing hyaluronic acid does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Formulations containing hyaluronic acid, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulations containing hyaluronic acid will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2135596